A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives

Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
05/2011
05/19/2011	WO2011059325A2 Dextran-hyaluronic acid based hydrogels
05/19/2011	WO2011059121A1 Salinomycin/inorganic-hydroxide nanohybrid material, pharmaceutical composition including same, and cancer treatment method using same
05/19/2011	WO2011059075A1 Glutamic acid-rich and arginine-rich preparation
05/19/2011	WO2011059073A1 Phospholipid derivative and ph-responsive liposomes
05/19/2011	WO2011059037A1 Pharmaceutical composition for external use
05/19/2011	WO2011058988A1 Antiviral agent-supporting sheet and method for producing same
05/19/2011	WO2011058764A1 Gargle preparation, and process and apparatus for production of same
05/19/2011	WO2011058573A1 Preservation of biomaterials
05/19/2011	WO2011058321A1 Conjugate molecule
05/19/2011	WO2011058165A1 Long-acting y2 receptor agonists
05/19/2011	WO2011058083A1 Pharmaceutical composition comprising a glp-1 agonist, an insulin, and methionine
05/19/2011	WO2011058082A1 Pharmaceutical composition comprising a glp-1 agonist and methionine
05/19/2011	WO2011058052A1 Direct protein delivery with engineered microvesicles
05/19/2011	WO2011057709A1 Anti integrin antibodies linked to nanoparticles loaded with chemotherapeutic agents
05/19/2011	WO2011011517A3 Iron preparation suitable for pharmaceutical formulation and process for the preparation thereof
05/19/2011	WO2011011351A3 A stable pharmaceutical omeprazole formulation for oral administration
05/19/2011	WO2011002852A3 Pro-drug complexes and related methods of use
05/19/2011	WO2010151073A3 Conjugates of anticancer chemotherapeutic agent-chlorine derivatives, photosensitizer containing same and composition for treating cancer containing same
05/19/2011	WO2010151020A3 Fast-dissolving oral film for effectively concealing unpleasant tastes
05/19/2011	WO2010148288A3 Pharmaceutical formulations with low aqueous levels of free unbound drug
05/19/2011	WO2010138392A3 Methods of treating chronic neurogenic inflammation using a modified clostridial toxin
05/19/2011	WO2010138384A3 Methods of treating chronic neurogenic inflammation using a modified clostridial toxin
05/19/2011	WO2010138366A3 Methods of treating chronic neurogenic inflammation using a modified clostridial toxin
05/19/2011	WO2010128087A9 Uses of immunoconjugates targeting cd138
05/19/2011	WO2010107831A8 Nanocarrier compositions and methods
05/19/2011	US20110118825 Anti-angiogenic compositions and methods of use
05/19/2011	US20110118532 Brachytherapy seed
05/19/2011	US20110118364 Pharmaceutical compositions of nanoparticles containing active ingredients
05/19/2011	US20110118363 Adhesive Composition
05/19/2011	US20110118362 Polymers for cardiopulmonary therapies
05/19/2011	US20110118361 Novel polymer particles and use thereof
05/19/2011	US20110118348 Methods of stabilizing latanoprost in an aqueous solution
05/19/2011	US20110117654 Buffer solution for electroporation and a method comprising the use of the same
05/19/2011	US20110117205 Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s)
05/19/2011	US20110117196 Analgetic dosage forms that are resistant to parenteral and inhalation dosing and have reduced side effects
05/19/2011	US20110117194 Pharmaceutical formulation containing angiotensin-ii receptor blocker
05/19/2011	US20110117190 Pharmaceutical Formulations
05/19/2011	US20110117184 Compositions for mucosal delivery of agents
05/19/2011	US20110117172 Cross-linked polymer matrix, in particular for administering active substances
05/19/2011	US20110117142 Method for coating tablets
05/19/2011	US20110117138 Charge-dynamic polymers and delivery of anionic compounds
05/19/2011	US20110117123 Multivalent Vaccine Composition With Mixed Carrier
05/19/2011	US20110117105 Method of treating immune disease using b-cell antibodies
05/19/2011	US20110117048 Method and composition for use in preparation of a patient for surgery
05/19/2011	US20110117019 Novel Compositions and Uses Thereof
05/19/2011	US20110117010 Methods and Compositions for Administering Therapeutic and Diagnostic Agents
05/19/2011	CA2780898A1 Advanced functional biocompatible foam used as a hemostatic agent for compressible and non-compressible acute wounds
05/19/2011	CA2780860A1 Pharmaceutical composition for external use
05/19/2011	CA2780773A1 Anti integrin antibodies linked to nanoparticles loaded with chemotherapeutic agents
05/19/2011	CA2780486A1 Stabilized formulations of fatty acids
05/19/2011	CA2780460A1 Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
05/19/2011	CA2780292A1 Nanosus pens ion of a poorly soluble drug made by microfluidization process
05/19/2011	CA2780234A1 Polysaccharide gel formulation having multi-stage bioactive agent delivery
05/19/2011	CA2780043A1 Pharmaceutical composition comprising a glp-1 agonist and methionine
05/19/2011	CA2778140A1 Dual variable domain immunoglobulins and uses thereof
05/19/2011	CA2776797A1 Pharmaceutical composition
05/18/2011	EP2322921A1 DNTP conjugated to peptide via a UV cleavable linker
05/18/2011	EP2322615A1 Use of unmethylated CpG oligonucleotides for the treatment of allergy
05/18/2011	EP2322608A1 Transfection agent
05/18/2011	EP2322569A2 Polymer derivates
05/18/2011	EP2322546A1 Acylated GLP-1 compounds
05/18/2011	EP2322243A1 Pharmaceutical products and compositions comprising formoterol, ciclesonide and tiotropium
05/18/2011	EP2322229A2 Remodelling and glycoconjugation of Granulocyte Colony Stimulating Factor (G-CSF)
05/18/2011	EP2322228A1 T cell receptor fusions and conjugates and methods of use thereof
05/18/2011	EP2322227A1 Ph-sensitive dendritic polymeric micelles
05/18/2011	EP2322226A2 Solutions and methods for inhibition of pain, inflammation and cartilage degradation
05/18/2011	EP2322212A1 Compositon of antigen and glycolipid adjuvant for sublingual administration
05/18/2011	EP2322209A2 Tumor specific oligosaccharide epitopes and use thereof
05/18/2011	EP2322183A1 Use of prodrugs for ocular intravitreous administration
05/18/2011	EP2322170A1 Minimizing adverse experience associated with oxybutynin therapy
05/18/2011	EP2322165A1 Apo2 ligand/TRAIL formulations
05/18/2011	EP2322160A1 Methods of inducing terminal differentiation
05/18/2011	EP2322158A2 Resveratrol and/or grape leaf extract for energy metabolism activation
05/18/2011	EP2322143A1 Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes
05/18/2011	EP2321358A1 Polysaccharides functionalised by tryptophan derivatives
05/18/2011	EP2320951A2 Galactosylated pro-drugs of non-steroidal anti-inflammatories with improved pharmacokinetic characteristics and reduced toxicity of the starting drug
05/18/2011	EP2320950A2 Peptides and their use as carriers into cancer cells
05/18/2011	EP2320949A2 Omega-3 enriched fish oil-in-water parenteral nutrition emulsions
05/18/2011	EP2320945A2 Stable anthrax vaccine formulations
05/18/2011	EP2320920A2 Topical anti-inflammatory combination
05/18/2011	EP2320915A1 Gentle, non-irritating, non-alcohoholic skin disinfectant
05/18/2011	EP2320913A1 Nucleic acid aptamers
05/18/2011	EP2320879A2 Pharmaceutical composition comprising jasmonates
05/18/2011	EP2320872A2 Process for preparing microparticles
05/18/2011	EP2320723A2 Foaming alcohol compositions with selected dimethicone surfactants
05/18/2011	EP2121742B1 Metastasis-specific peptides and their diagnostic and therapeutic applications
05/18/2011	EP2101571B1 Ornithine conjugates of amphetamine and processes for making and using the same
05/18/2011	EP1786397B1 Phenytoin formulations, and uses thereof in wound healing
05/18/2011	EP1625334B1 Percussively ignited self-contained heating unit
05/18/2011	EP1539664B1 Crystallization of polyol compositions, crystalline polyol composition product and use thereof
05/18/2011	EP1499359B1 Temperature responsive delivery systems
05/18/2011	EP1478764B1 Humanized collagen antibodies and related methods
05/18/2011	EP1379499B1 New diaminedithiol derivatives and radiorhenium or radiotechnetium complex thereof; a liver cancer-treating composition comprising the radiorhenium complex and lipiodol; and a kit for preparation of the liver cancer-treating composition
05/18/2011	CN1919210B System for the liberation of an active principle and its use
05/18/2011	CN102066438A Water-soluble acrylic acid salt polymer and gelling base
05/18/2011	CN102066405A Supercharged proteins for cell penetration
05/18/2011	CN102066402A Peptide derivative and composition for promoting tear secretion comprising the same
05/18/2011	CN102065989A Microcapsule, process for production thereof, and food or beverage containing microcapsule
05/18/2011	CN102065903A Insulin albumin conjugates
05/18/2011	CN102065902A Polymeric carrier

1 ... 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 ... 1712